Fennec Pharmaceuticals Inc. (FENC) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $11.25, but acceptable to hold if already in. Reasons: Market cap $396M below $400M minimum; Value-trap signals (2/5): Margin compression (op margin -49.5%), Negative free cash flow.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its... Read more
Hold if already holding. Not a fresh buy at $11.25, but acceptable to hold if already in. Reasons: Market cap $396M below $400M minimum; Value-trap signals (2/5): Margin compression (op margin -49.5%), Negative free cash flow. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $396M below $400M minimum. Not in investable universe. Score 6.5/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-08-22Recent Developments — Fennec Pharmaceuticals Inc.
Latest news
- NEWS Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade) - Seeking Alpha — Seeking Alpha negative
- NEWS Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research — Zacks Investment Research neutral
- NEWS Fennec (FENC) Technical Check: Adds 0.51% to Close at $11.89 at the Close; Current Setup: the Supplied Trading Band Runs — Vinanet neutral
- NEWS Fennec Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $16.17, Implies 48% Upside - TradingView — TradingView positive
- NEWS FENNEC PHARMACEUTICALS ($FENC) Releases Q2 2026 Earnings - Quiver Quantitative — Quiver Quantitative neutral
Generated 2026-08-23T00:51:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $11.25, but acceptable to hold if already in. Reasons: Market cap $396M below $400M minimum; Value-trap signals (2/5): Margin compression (op margin -49.5%), Negative free cash flow. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $396M below $400M minimum. Not in investable universe. Target $15.37 (+36.6%), stop $10.50 (−7.1%), A.R:R 2.4:1. Score 6.5/10, moderate confidence.
Take-profit target: $15.37 (+36.1% upside). Target $15.37 (+36.6%), stop $10.50 (−7.1%), A.R:R 2.4:1. Stop-loss: $10.50.
Market cap $396M below $400M minimum; Value-trap signals (2/5): Margin compression (op margin -49.5%), Negative free cash flow.
Fennec Pharmaceuticals Inc. trades at a P/E of N/A (forward 11.9). TrendMatrix value score: 7.9/10. Verdict: Hold.
12 analysts cover FENC with a consensus score of 4.2/5. Average price target: $18.
What does Fennec Pharmaceuticals Inc. do?Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The...
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.